secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0000950170-25-005435
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics outlines 2025 milestones: paltusotine PDUFA Sept 25, atumelnant Ph3 start H1 2025
--------------------------------------------------------------------------------

- Paltusotine NDA under FDA review; PDUFA target action date set for September 25, 2025.
- Atumelnant Phase 3 initiation for adult CAH patients expected in H1 2025; pediatric CAH and Cushing's disease later-stage trials planned in 2025.
- Four development candidates advancing toward IND-enabling studies for NETs, hyperparathyroidism, Graves' disease, thyroid eye disease, and ADPKD.
- CEO Scott Struthers presenting at 43rd J.P. Morgan Healthcare Conference on January 14, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025005435/0000950170-25-005435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025005435/crnx-20250114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-005435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer